The combination of OV therapy with PD-1/PD-L1 immunotherapy provided a synergistic effect leading to an improved overall survival and an activation of the immune response capable to reverse the tumor-induced immune suppression [142,143]. The gene discussed is PDCD1; the disease is neoplasm.